US 12,456,545 B2
Systems and methods for providing professional treatment guidance for diabetes patients
Robert Maurer, Moraga, CA (US); and Barry Ginsberg, Moraga, CA (US)
Assigned to TIGAR HEALTH, INC., Moraga, CA (US)
Filed by TIGAR Health, Inc., Moraga, CA (US)
Filed on Aug. 6, 2021, as Appl. No. 17/396,496.
Application 17/396,496 is a continuation of application No. 16/179,429, filed on Nov. 2, 2018, granted, now 11,107,565.
Claims priority of provisional application 62/580,889, filed on Nov. 2, 2017.
Prior Publication US 2022/0093227 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G16H 15/00 (2018.01); A61B 5/00 (2006.01); G16B 40/00 (2019.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 50/20 (2018.01)
CPC G16H 15/00 (2018.01) [A61B 5/4866 (2013.01); G16B 40/00 (2019.02); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 50/20 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method for treating a patient having a diabetic or pre-diabetic condition, the method comprising:
obtaining a biochemical data set, via a computer system having a processor programmed to obtain the biochemical data set, wherein the biochemical data set comprises a plurality of test results from a single blood draw of the patient, wherein the plurality of test results comprises at least three measurements from the group consisting of a high-sensitivity c-reactive protein test, an adiponectin level test, a proinsulin level test, an insulin level test, a C-peptide test, a HbA1c test, and an eGFR level test;
obtaining a demographic data set for the patient, via a computer system having a processor programmed to obtain the biochemical data set, wherein the demographic data set comprises (i) an indication of a gender of the patient and (ii) an enumerated indication of a patient's stage of disease or a current therapy, wherein the enumerated indication of the patient's stage of disease or the current therapy is one of (a) diagnosed as pre-diabetes, (b) diagnosed with diabetes but not taking a drug, (c) diagnosed with diabetes and taking a first line diabetes drug, (d) diagnosed with diabetes and prescribed multiple diabetes drugs without insulin, (e) diagnosed with diabetes and prescribed multiple diabetes drugs with insulin, or (f) a current therapy for the diabetic or pre-diabetic condition;
running all or a portion of the biochemical data set and the demographic data set against a plurality of decision rules via a computer system having a processor programmed to perform the running, wherein, in accordance with a determination that one or more firing conditions of each respective decision rule in the plurality of decision rules is fired, a patient pattern is selected, from among a set of at least 20,000 patient patterns, through the comparison of (i) the determination that one or more firing conditions of each respective decision rule in the plurality of decision rules is fired to (ii) each patient pattern in the set of at least 20,000 patient patterns, wherein the patient pattern comprises a pattern of insulin resistance, β-cell stress level, and cardiovascular inflammation;
determining a first prioritization of intervention classes in a first priority ordering of a plurality of intervention classes for the diabetic or pre-diabetic condition based on the identity of the patient pattern; and
using the first prioritization of intervention classes to select and provide a new therapy or an altered therapy to the patient for the diabetic or pre-diabetic condition, wherein the new therapy or the altered therapy comprises administering to the patient at least one drug that is in the group consisting of a metformin class, a sodium-glucose cotransporter-2 inhibitor class, a glucagon-like-peptide-1 receptor agonists class, a dipeptidyl peptidase-4 inhibitor class, an insulin class, a thiazolidinedione class, a glinides class, and a sulfonylurea class.